Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.81 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.65 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.65 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9506671 | 1.00 | FAAH (0.81) | FAAHITGB3ITGA2BPSMB5HDAC3 | |
| SCHEMBL9716823 | 1.00 | FAAH (0.81) | FAAHITGB3ITGA2BPSMB5HDAC3 | |
| SCHEMBL1815009 | 1.00 | FAAH (0.81) | FAAHITGB3ITGA2BPSMB5HDAC3 | |
| SCHEMBL1815011 | 1.00 | FAAH (0.81) | FAAHITGB3ITGA2BPSMB5HDAC3 | |
| SCHEMBL9666114 | 1.00 | FAAH (0.81) | FAAHITGB3ITGA2BPSMB5HDAC3 | |
| SCHEMBL22494096 | 1.00 | FAAH (0.81) | FAAHITGB3ITGA2BPSMB5HDAC3 | |
| SCHEMBL22494095 | 1.00 | FAAH (0.81) | FAAHITGB3ITGA2BPSMB5HDAC3 | |
| SCHEMBL21998924 | 1.00 | FAAH (0.81) | FAAHITGB3ITGA2BPSMB5HDAC3 | |
| SCHEMBL22494097 | 1.00 | FAAH (0.81) | FAAHITGB3ITGA2BPSMB5HDAC3 | |
| SCHEMBL15285319 | 1.00 | FAAH (0.81) | FAAHITGB3ITGA2BPSMB5HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891764-A1 | N-acylamino acids and cosmetics using the same | KASHIMA OIL COMPANY (JP) | 1999-01-20 | — | — | EP | claimed |
| JP-11080105-A | — | — | None | — | — | JP | disclosed |
| EP-4662197-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2025-12-17 | — | — | EP | disclosed |
| US-12194080-B2 | Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2024165426-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2024-08-15 | — | — | WO | disclosed |
| EP-4414360-A1 | METHOD FOR PURIFICATION OF AMINO ACID SURFACTANTS | BASF SE (DE) | 2024-08-14 | — | — | EP | disclosed |
| EP-3368157-B1 | METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING PM20D1 AND N-LIPIDATED AMINO ACIDS | DANA FARBER CANCER INST INC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20210106661-A1 | METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING PM20D1 AND N-LIPIDATED AMINO ACIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-15 | — | — | US | disclosed |
| EP-1309336-B1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | BIOSOURCE PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1309336-A4 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | MICROLOGIX BIOTECH INC (CA) | 2005-01-05 | — | — | EP | disclosed |
| US-6737403-B2 | CULTURING MICROORGANISM STREPTOMYCES VIRIDOCHROMOGENES, SSP. KOMABENSIS (ATCC 29814) IN CULTURE MEDIUM, ISOLATING LASPARTOMYCIN, CLEAVING LIPOPHILIC FRAGMENT FROM LASPARTOMYCIN, THEREBY YIELDING LASPARTOMYCIN CORE PEPTIDE | MICROLOGIX BIOTECH INC. (CA) | 2004-05-18 | — | — | US | disclosed |
| EP-0891764-B1 | Ethanolic solutions of N-pentadecanoylisoleucine and use thereof in cosmetics | KASHIMA OIL (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-1309336-A1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | Micrologix Biotech, Inc. (CA) | 2003-05-14 | — | — | EP | disclosed |
| US-20020035063-A1 | Derivatives of laspartomycin and preparation and use thereof | BIOSOURCE PHARM, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002005838-A1 | DERIVATIVES OF LASPARTOMYCIN AND PREPARATION AND USE THEREOF | INTRABIOTICS PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| JP-H1180105-A | N-ACYLAMINO ACID AND COSMETIC USING THE SAME | KASHIMA SEKIYU KK | 1999-03-26 | — | — | JP | disclosed |
| EP-0891764-A1 | N-acylamino acids and cosmetics using the same | KASHIMA OIL COMPANY (JP) | 1999-01-20 | — | — | EP | disclosed |
| EP-0891764-A1 | N-acylamino acids and cosmetics using the same | KASHIMA OIL COMPANY (JP) | 1999-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035063-A1 | Derivatives of laspartomycin and preparation and use thereof | VIP, LAS1L, PREP | FAAH 1789/4885ITGB3 4515/4885ITGA2B 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.